Training: Penn State (PH.D), Harvard medical school (post-Dr)
Research Overview: Min Gao is a virologist and has worked for Arbutus Biopharma and Bristol-Myers Squibb (BMS) company.  His group was focused on antiviral drug development and mode of inhibition.  His team was the first to successfully discover hepatitis C virus (HCV) NS5A replication complex inhibitors. This work led to the development of Daclatasvir (DCV) with unprecedented in vitro potency (pM to low nM) and remarkable clinical efficacy. Development of effective HCV combination therapy is one of the most successful stories in anti-viral therapy, whileNS5A inhibitor is an essential component of all interferon/ribavirin-free regimens in currently approved HCV therapies.

Research Projects: Herpes virus protease, HBV, HCV, Dengue virus, and SARS-CoV2 polymease